News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

ZIOPHARM, Inc. Announces FDA Acceptance of IND for Oral Palifosfamide


2/6/2012 9:52:18 AM

NEW YORK, Feb. 6, 2012 (GLOBE NEWSWIRE) -- ZIOPHARM Oncology, Inc. (Nasdaq:ZIOP), a biopharmaceutical company with small molecule and synthetic biology approaches to new cancer therapies, announced today that the U.S. Food and Drug Administration (FDA) has accepted its investigational new drug (IND) application for the oral dosing of palifosfamide (Zymafos® or ZIO-201), a form of administration offering several potential patient-oriented advantages and an outpatient treatment for expanded global commercial reach.

Read at GlobeNewswire


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES